-
Clinical trial of Taletrectinib in the treatment of NTRK fusion solid tumors completed the first patient administration
Time of Update: 2021-06-28
Innovent announced today that the second phase basket trial of taletrectinib in the treatment of NTRK fusion solid tumors has completed the first patient administration (NCT04617054) .
-
Is the double antibody necessarily better than the monoclonal antibody?
Time of Update: 2021-06-28
Is there an advantage over existing treatments?Answering these questions requires a basic knowledge: how much do you know about the disease?Two separate and effective antibodies, combined together, some increase the efficacy, while others will bring side effects and increase toxicity.
-
Challenge the biology textbook!
Time of Update: 2021-06-28
> . >>However, a new study published in the journal Science Advances by researchers from Thomas Jefferson University found that there is a retrograde "polymerase θ (Pol
-
Anti-customer-oriented: small molecule synthetic receptors conquer drug-resistant bacteria
Time of Update: 2021-06-28
Recently, Israeli scientists discovered that a class of small molecule synthetic receptors (also called molecular tweezers) can inhibit the biofilm formation of drug-resistant staphylococci
-
After 10 years of follow-up, it was found that ultra-processed food not only harms the child’s present but also affects the future
Time of Update: 2021-06-28
2 years, it was found that, in general, children who ate too much ultra-processed food increased their body mass index, weight, waist circumference, and body fat faster when they entered adolescence and early adulthood .
-
How to solve the problem of antibiotic abuse?
Time of Update: 2021-06-28
Therefore, the researchers started from this, selecting the two most common human pathogens-Staphylococcus aureus and Gram-negative Pseudomonas aeruginosa, and using computer simulation and in vivo detection methods to screen and verify that they can target H2S Small molecule compounds .
-
The first heat shock inducer Miplyffa was rejected by the U.S. FDA
Time of Update: 2021-06-28
Original source: Orphazyme provides regulatory update from FDA on arimoclomol for Niemann-Pick disease type C
-
Bairen Medical: RenatusTM interventional aortic valve system passed the review of the ethics committee
Time of Update: 2021-06-28
>On June 17, Bairen Medical announced that the research product RenatusTM interventional aortic valve system (TAVR) passed the review of the ethics committee at the Beijing
-
JAMA Sub-Journal: What are the consequences of discontinuing statins?
Time of Update: 2021-06-28
Recently, a study published in JAMA Network Open, a sub-journal of JAMA, showed that for people 65 years and older, if statins are stopped, the risk of fatal and non-fatal cardiovascular disease may be higher .
-
Challenge Novartis Rydapt!
Time of Update: 2021-06-28
Data released by Blueprint showed that 92% of patients with therapeutic response had to reduce the dose of Ayvakit from 200 mg at the beginning of the trial to 100 mg or even lower due to side effects .
-
A lot of fat is found in the tumor!
Time of Update: 2021-06-28
Following this problem, the researchers found that the T cells in these tumor microenvironments would ingest a large amount of oxidized fat, inhibiting the function of T cells .
-
Zynlonta has significant efficacy in the treatment of malignant lymphoma and has been approved for clinical trials in China
Time of Update: 2021-06-28
Data from the key LOTIS-2 trial showed that among patients with heavily-preteated (previously received multiple therapies) r/r DLBCL, the overall response rate (ORR) of Zynlonta monotherapy reached 48.
-
The first CAR-T therapy in China!
Time of Update: 2021-06-28
in large quantities and then infused back into the patient's body, thereby increasing the survival rate of CAR-T cells in the body . Once CAR-T cells survive in the patient's body
-
PNAS: cGAS limits the development of colon cancer by protecting the integrity of the intestinal barrier
Time of Update: 2021-06-28
These results indicate that cGAS has a unique role in protecting the intestinal epithelial barrier and preventing the development of colon cancer .
-
Early lung cancer cells may "draw up" immune cells to help tumors invade lung tissues
Time of Update: 2021-06-28
from the patient entering the operating room to remove the cancer lesions, and then analyzes the patient’s lung tumor samples, samples around healthy lung tissue, and blood samples at the cellular level. , So as to draw a map of the immune
-
Hutchison Medicine Sofantinib is approved for the treatment of advanced pancreatic neuroendocrine tumors
Time of Update: 2021-06-28
SANET-p study primary endpoint resultsOn December 30, 2020, Sofatinib was approved by the National Food and Drug Administration for the treatment of non-pancreatic neuroendocrine tumors .
-
One treatment is expected to be cured for life?
Time of Update: 2021-06-28
/>. As a new field in the treatment of cancer and genetic diseases, CGT therapy is currently a very promising development direction in the field of biomedicine .
-
The clinical development of BioVaxys is actively reviewed by the FDA
Time of Update: 2021-06-28
BioVaxys submitted CoviDTH's pre-IND meeting application and briefing package to the FDA's Center for Biologics Evaluation and Research (CBER) in March this year .
-
"Nature": The 100th Anniversary of Insulin Discovery See Ten Monuments of Diabetes Treatment
Time of Update: 2021-06-28
> . However, the precise link between these complications and blood sugar control has not received enough attention . The Belgian doctor Jean Pirart published
-
Gan Lai announces that FXR agonist ASC42 has achieved good data in phase I clinical trials in the United States
Time of Update: 2021-06-28
The top-line data of ASC42 Phase I showed that during the 14-day, once-daily, 15mg each time treatment, the biomarker FGF19 activated by FXR was displayed on the 1st and 14th days respectively compared with that before the administration.
